{{medical}}
[[Image:Sildenafil.svg|thumb]] (威而剛) 的分子結構]]

'''第五型磷酸二酯酶抑制劑'''（phosphodiesterase type 5 inhibitor）也稱為'''PDE5抑制剂'''，是一種抑制{{Tsl|en|cGMP-specific_phosphodiesterase_type_5|第五型環磷酸鳥苷特異性磷酸二酯酶}}對血管內壁[[平滑肌|平滑肌]]細胞中的[[環磷酸鳥苷|環磷酸鳥苷]]分解作用的[[藥物|藥物]]<ref>{{Cite journal |title=A comparison of the available phosphodie­sterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil |url=https://www.dovepress.com/a-comparison-of-the-available-phosphodieshysterase-5-inhibitors-in-the-peer-reviewed-article-PPA |last=Hill |first=Stephen R. |last2=Evans |first2=Jeffery D. |date=2015-08-12 |doi=10.2147/ppa.s56002 |language=en |pmid=26316720 |journal= |author= |access-date=2019-01-05 |archive-url=https://web.archive.org/web/20180602211843/https://www.dovepress.com/a-comparison-of-the-available-phosphodieshysterase-5-inhibitors-in-the-peer-reviewed-article-PPA |archive-date=2018-06-02 |dead-url=no }}</ref>。透過抑制[[陰莖海綿體|陰莖海綿體]]血管中的[[環磷酸鳥苷|環磷酸鳥苷]]分解，這類藥物是最早被核准用於治療[[勃起功能障礙|勃起功能障礙]]的有效口服藥物。由於其作用對象第五型環磷酸鳥苷特異性磷酸二酯酶也存在[[肺|肺臟]]的[[動脈|動脈]]平滑肌當中，第五型磷酸二酯酶抑制劑也可用於治療[[肺高壓|肺高壓]]<ref name="molemech">{{Cite journal |title=Mechanisms of action of PDE5 inhibition in erectile dysfunction |url=https://www.nature.com/articles/3901205 |last=Corbin |first=J. D. |date=2004-06-06 |journal=International Journal of Impotence Research |issue=S1 |doi=10.1038/sj.ijir.3901205 |volume=16 |pages=S4–S7 |language=en |issn=1476-5489}}</ref>。

==適應症與禁忌症==

[[西地那非|西地那非]]、{{tsl|en|tadalafil|他達拉非}}以及[[伐地那非|伐地那非]]等第五型磷酸二酯酶抑制劑在臨床上被用於治療勃起功能障礙<ref>{{cite book| title=Male Sexual Dysfunction: Pathophysiology and Treatment | author= Fouad R. Kandeel | publisher= CRC Press, 2013|page=453| chapter = Treatment of Erectile Dsyfunction in Men with Heart Disease}}</ref>。當中[[西地那非|西地那非]]與{{tsl|en|tadalafil|他達拉非}}也被核准用來治療[[肺高壓|肺高壓]]<ref>{{Cite journal |title=Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator |url=https://www.ecrjournal.com/articles/pulmonary-arterial-hypertension-phosphodiesterase-type-5-inhibitors |last=Watanabe |first=Hiroshi |date=2018 |journal=European Cardiology Review |issue=1 |doi=10.15420/ecr.2017:22:2 |volume=13 |pages=35 |language=en |issn=1758-3756}}</ref>。[[西地那非|西地那非]]是最早被發現的第五型磷酸二酯酶抑制劑，它在尋找治療[[心絞痛|心絞痛]]的新藥時被發現，2002年的研究指出它能促進[[中風|中風]]後的[[神經發生|神經增生]]<ref>{{cite journal |doi=10.1161/01.STR.0000034399.95249.59 |title=Sildenafil (Viagra) Induces Neurogenesis and Promotes Functional Recovery After Stroke in Rats |year=2002 |last1=Zhang |first1=R. |journal=Stroke |volume=33 |issue=11 |pages=2675–80 |pmid=12411660 |last2=Wang |first2=Y |last3=Zhang |first3=L |last4=Zhang |first4=Z |last5=Tsang |first5=W |last6=Lu |first6=M |last7=Zhang |first7=L |last8=Chopp |first8=M}}</ref>。

第五型磷酸二酯酶抑制劑可以單獨使用也可以與其他藥物併用治療肺高壓。相對於其他肺高壓用藥，它的作用時間較長且副作用較少<ref>{{Cite journal |title=Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics |author=Julio D Duarte, Rebekah L Hanson, Roberto F Machado |url=https://www.futuremedicine.com/action/captchaChallenge?redirectUrl=https%3A%2F%2Fwww.futuremedicine.com%2Fdoi%2F10.2217%2Ffca.13.6& |journal=Future Medicine |doi=10.2217/fca.13.6 |year=2013-05-14 |pmc=3864092 |pmid=23668740}}</ref>。目前證據顯示使用第五型磷酸二酯酶抑制劑的肺高壓患者的心肺功能得到改善，但還不清楚用藥是否可以改善存活率<ref>{{Cite journal |title=The molecular targets of approved treatments for pulmonary arterial hypertension |url=https://thorax.bmj.com/content/71/1/73 |last=Ghofrani |first=Hossein-Ardeschir |last2=Humbert |first2=Marc |date=2016-01-01 |journal=Thorax |issue=1 |doi=10.1136/thoraxjnl-2015-207170 |volume=71 |pages=73–83 |language=en |issn=1468-3296 |pmc=4717417 |pmid=26219978 |author= |access-date=2019-01-05 |archive-url=https://web.archive.org/web/20180601202730/http://thorax.bmj.com/content/71/1/73 |archive-date=2018-06-01 |dead-url=no }}</ref>。

第五型磷酸二酯酶抑制劑不可與[[單硝酸異山梨酯|單硝酸異山梨酯]]與[[硝酸異山梨酯|硝酸異山梨酯]]等[[硝酸鹽|硝酸鹽]]類藥物同時服用，同時服用產生的藥物交互作用可能造成致命性低血壓或[[心肌梗死|心肌梗死]]<ref>{{cite web|url=http://www.clinicalpharmacology-ip.com/Forms/Reports/intereport.aspx?gpcid=2519,2968&l=0|title=Clinical Pharmacology|author=|date=|website=www.clinicalpharmacology-ip.com}}</ref>，因心血管疾病風險被醫師建議不可進行性行為的人也不可服用第五型磷酸二酯酶抑制劑<ref name=Rossi>Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.{{page needed|date=January 2013}}</ref>。

==不良反應==

第五型磷酸二酯酶抑制劑造成的[[藥物不良反應|藥物不良反應]]常與服用劑量有關<ref>{{Cite web |url=https://www.rxlist.com/viagra-side-effects-drug-center.htm |title=Common Side Effects of Viagra (Sildenafil Citrate) Drug Center |accessdate=2019-01-05 |work=RxList |language=en |archiveurl=https://web.archive.org/web/20190105212102/https://www.rxlist.com/viagra-side-effects-drug-center.htm |archivedate=2019-01-05}}</ref>。[[頭痛|頭痛]]是常見的不良反應之一，在服用第五型磷酸二酯酶抑制劑的病人中發生率超過百分之十<ref>{{cite web |author1=Mayo Clinic |title=Sildenafil (Oral Route) |url=https://www.mayoclinic.org/drugs-supplements/sildenafil-oral-route/side-effects/drg-20066989 |website=mayoclinic.org |publisher=Mayo Clinic |accessdate=2018-12-31 |archive-url=https://web.archive.org/web/20170602235017/http://www.mayoclinic.org/drugs-supplements/sildenafil-oral-route/side-effects/drg-20066989 |archive-date=2017-06-02 |dead-url=no }}</ref>。其他常見的不良反應包括[[頭暈|頭暈]]、{{tsl|en|flushing|潮紅}}、[[消化不良|消化不良]]、[[鼻塞|鼻塞]]或[[鼻炎|鼻炎]]等<ref>{{cite journal |last1=Kiroglu |first1=A. Faruk |last2=Bayrakli |first2=Hasmet |last3=Yuca |first3=Koksal |last4=Cankaya |first4=Hakan |last5=Kiris |first5=Muzaffer |title=Nasal Obstruction as a Common Side-Effect of Sildenafil Citrate |journal=The Tohoku Journal of Experimental Medicine |date=2006 |volume=208 |issue=3 |pages=251–254 |doi=10.1620/tjem.208.251 |pmid=16498233 |url=https://www.jstage.jst.go.jp/article/tjem/208/3/208_3_251/_article |accessdate=2018-12-31 |author= |archive-url=https://web.archive.org/web/20180610153404/https://www.jstage.jst.go.jp/article/tjem/208/3/208_3_251/_article |archive-date=2018-06-10 |dead-url=no }}</ref>。

[[美國食品藥物監督管理局|美國食品藥物監督管理局]]於 2007 年將[[聽覺障礙|突發性聽覺障礙]]列入第五型磷酸二酯酶抑制劑包裝上的警示<ref name="FDA PDE5">{{cite web| url= http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm| title= FDA Announces Revisions to Labels for Cialis, Levitra and Viagra| author= | date= 2007-10-18| publisher= [[Food_and_Drug_Administration|Food and Drug Administration]]| accessdate= 2011-10-30| archive-url= https://web.archive.org/web/20161022203200/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm| archive-date= 2016-10-22| dead-url= no}}</ref>。同年也有研究指出第五型磷酸二酯酶抑制劑可能造成{{tsl|en|Anterior_ischemic_optic_neuropathy|前部視神經缺血性病變}}<ref name="Optic neuropathy">{{cite journal |doi=10.1111/j.1464-410X.2007.06839.x |title=The Phosphodiesterase Inhibitors and Non-Arteritic Anterior Ischaemic Optic Neuropathy: Increased Vigilance is Necessary |year=2007 |last1=Rao |first1=Amrith R. |last2=Thwaini |first2=Ali |last3=Ahmed |first3=Hashim U. |last4=Shergill |first4=Iqbal S. |last5=Minhas |first5=Suks |journal=BJU International |volume=100 |pages=3–4 |pmid=17488310 |issue=1}}</ref>。特定的第五型磷酸二酯酶抑制劑有各自的不良反應，這些不良反應會在藥物各自的專屬頁面中列出。

==藥物交互作用==
第五型磷酸二酯酶抑制劑主要由[[細胞色素P450|細胞色素P450]]中的[[CYP3A4|CYP3A4]]代謝<ref name = "PnT">{{Cite journal |title=Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction |url=https://www.ncbi.nlm.nih.gov/pubmed/24049429 |last=Huang |first=Sharon A. |last2=Lie |first2=Janette D. |date=2013-7 |journal=P & T: A Peer-Reviewed Journal for Formulary Management |issue=7 |volume=38 |pages=407–419 |issn=1052-1372 |pmc=3776492 |pmid=24049429 |author= |access-date=2019-01-05 |archive-url=https://web.archive.org/web/20140816185718/http://www.ncbi.nlm.nih.gov/pubmed/24049429 |archive-date=2014-08-16 |dead-url=no }}</ref>，因此能抑制或強化[[CYP3A4|CYP3A4]]作用的藥物都與第五型磷酸二酯酶抑制劑有潛在的交互作用。與第五型磷酸二酯酶抑制劑有潛在交互作用的藥物包括用在抗逆轉錄病毒藥物的[[蛋白酶抑制劑|蛋白酶抑制劑]]、[[酮康唑|酮康唑]]、以及[[伊曲康唑|伊曲康唑]]<ref name=Rossi/><ref>{{cite web |author1=Pfizer Medical Information |title=VIAGRA® (sildenafil citrate): Drug interactions |url=https://www.pfizermedicalinformation.com/en-us/viagra/drug-interactions |website=Pfizer Medical Information |publisher=Pfizer |accessdate=2018-12-31 |archive-url=https://web.archive.org/web/20190101102021/https://www.pfizermedicalinformation.com/en-us/viagra/drug-interactions |archive-date=2019-01-01 |dead-url=no }}</ref>。另外，第五型磷酸二酯酶抑制劑不可與[[季戊四醇四硝酸酯|季戊四醇四硝酸酯]]或[[硝酸甘油|硝酸甘油]]等[[硝酸鹽|硝酸鹽]]類[[血管舒張|血管擴張劑]]併用，因併用時可能引發嚴重的[[低血壓|低血壓]]，甚至可能造成生命危險<ref name="AustriaCodex">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=978-3-85200-196-8|language=de}}</ref>。

==代表藥物==
[[西地那非|西地那非]]（{{lang-en|Sildenafil}}）是首個被發現的第五型磷酸二酯酶抑制劑<ref name = "PnT"/>，其他的衍生藥物包括有自然生成或合成的的第五型磷酸二酯酶抑制劑。

*{{tsl|en|avanafil|阿伐那非}}
*{{tsl|en|lodenafil|羅地那非}}
*{{tsl|en|mirodenafil|米羅那非}}
*[[西地那非|西地那非]]
*{{tsl|en|tadalafil|他達拉非}}
*[[伐地那非|伐地那非]]
*{{tsl|en|udenafil|烏地那非}}
*{{tsl|en|zaprinast|紮普司特}}
* {{tsl|en|Icariin|淫羊藿甙}}：原為一[[天然產物|天然產物]]，其抑制效果較弱，且目前僅有體外實驗證據<ref>{{cite journal |doi=10.1007/s11596-006-0421-y |title=Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum |year=2006 |last1=Jiang |first1=Zhaojian |last2=Hu |first2=Benrong |last3=Wang |first3=Jialing |last4=Tang |first4=Qiang |last5=Tan |first5=Yan |last6=Xiang |first6=Jizhou |last7=Liu |first7=Juyan |journal=Journal of Huazhong University of Science and Technology |volume=26 |issue=4 |pages=460–2 |pmid=17120748}}</ref><ref>{{cite journal |doi=10.1016/j.urology.2006.09.031 |title=Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells |year=2006 |last1=Ning |first1=Hongxiu |last2=Xin |first2=Zhong-Cheng |last3=Lin |first3=Guiting |last4=Banie |first4=Lia |last5=Lue |first5=Tom F. |last6=Lin |first6=Ching-Shwun |journal=Urology |volume=68 |issue=6 |pages=1350–4 |pmid=17169663}}</ref>，後續也開發出此分子的化學[[衍生物|衍生物]]<ref>{{cite journal |doi=10.1021/np800049y |title=Potent Inhibition of Human Phosphodiesterase-5 by Icariin Derivatives |year=2008 |last1=Dell'Agli |first1=Mario |last2=Galli |first2=Germana V. |last3=Dal Cero |first3=Esther |last4=Belluti |first4=Federica |last5=Matera |first5=Riccardo |last6=Zironi |first6=Elisa |last7=Pagliuca |first7=Giampiero |last8=Bosisio |first8=Enrica |journal=Journal of Natural Products |volume=71 |issue=9 |pages=1513–7 |pmid=18778098}}</ref>。
* {{tsl|en|benzamidenafil|本紮那非}}
*[[達生他非|達生他非]]（Dasantafil）

上列藥物雖然均偏好抑制第五型磷酸二酯酶，但並非絕對專一，尤其在高劑量時亦可能抑制其他[[酵素|酵素]]的作用。舉例來說，[[西地那非|西地那非]]也會抑制{{tsl|en|PDE6|第六型磷酸二酯酶}}與{{tsl|en|PDE9|第九型磷酸二酯酶}}，對於第六型磷酸二酯酶的抑制被認為是視覺異常副作用的主要機轉<ref>{{cite journal ||last1=Stockman |first1=Andrew |last2=Sharpe |first2=Lindsay T. |last3=Tufail |first3=Adnan |last4=Kell |first4=Philip D. |last5=Ripamonti |first5=Caterina |last6=Jeffery |first6=Glen |title=The effect of sildenafil citrate (Viagra®) on visual sensitivity |journal=Journal of Vision |date=2007-06-08 |volume=7 |issue=8 |pages=4 |doi=10.1167/7.8.4 |pmid=17685811 |accessdate=2018-12-31}}</ref>。同樣的，{{tsl|en|tadalafil|他達拉非}}不只會抑制第五型，它也會作用在{{tsl|en|PDE11|第十一型磷酸二酯酶}}<ref>{{cite journal |last1=Bischoff |first1=E |title=Potency, selectivity and consequences of nonselectivity of PDE inhibition |journal=International Journal of Impotence Research |date=2004-06-06 |volume=16 |issue=S1 |pages=S11–S14 |doi=10.1038/sj.ijir.3901208 |url=https://www.nature.com/articles/3901208 |accessdate=2018-12-31 |author= |archive-url=https://web.archive.org/web/20181101083735/http://www.nature.com/articles/3901208 |archive-date=2018-11-01 |dead-url=no }}</ref>。雖然具有非專一性作用的潛力，現有第五型磷酸二酯酶抑制劑的專一性在臨床實務上已經足夠，非專一性作用一般並不造成問題。

[[咖啡因|咖啡因]]是一種非專一性的磷酸二酯酶抑制劑，在非毒性劑量下會抑制第五型磷酸二酯酶。咖啡因抑制第五型磷酸二酯酶的機轉與[[西地那非|西地那非]]相似<ref>{{Cite journal|last=Ribeiro|first=Joaquim A.|last2=Sebastião|first2=Ana M.|date=2010-04-14|title=Caffeine and Adenosine|url=https://content.iospress.com:443/articles/journal-of-alzheimers-disease/jad01379|journal=Journal of Alzheimer's Disease|language=en|volume=20|issue=s1|pages=S3–S15|doi=10.3233/jad-2010-1379|pmid=20164566|issn=1875-8908|author=|access-date=2019-01-06|archive-url=https://web.archive.org/web/20180925221231/https://content.iospress.com/articles/journal-of-alzheimers-disease/jad01379|archive-date=2018-09-25|dead-url=no}}</ref><ref>{{Cite journal|last=Daly|first=J. W.|date=August 2007|title=Caffeine analogs: biomedical impact|journal=Cellular and Molecular Life Sciences: CMLS|volume=64|issue=16|pages=2153–2169|doi=10.1007/s00018-007-7051-9|issn=1420-682X|pmid=17514358|url=https://ze**no**do.org/record/1232583|type=Submitted manuscript}}</ref>。

==作用機轉==
[[勃起|勃起]]的過程有一部分需要[[一氧化氮|一氧化氮]]的參與，在受到性刺激後，[[一氧化氮|一氧化氮]]會在[[陰莖海綿體|陰莖海綿體]]的血管中釋放，並活化{{tsl|en|guanylate_cyclase|鳥苷酸環化酶}}，使[[環磷酸鳥苷|環磷酸鳥苷]]的濃度上升。高濃度的[[環磷酸鳥苷|環磷酸鳥苷]]使得血管壁的[[平滑肌|平滑肌]]舒張，並增加[[陰莖海綿體|陰莖海綿體]]中的血流供應而造成勃起<ref>{{cite journal |last1=Cartledge |first1=J |last2=Minhas |first2=S |last3=Eardley |first3=I |title=The role of nitric oxide in penile erection. |journal=Expert opinion on pharmacotherapy |date=2001-01 |volume=2 |issue=1 |pages=95-107 |doi=10.1517/14656566.2.1.95 |pmid=11336572 |accessdate=2018-12-31}}</ref>。第五型磷酸二酯酶抑制劑阻止第五型磷酸二酯酶分解[[環磷酸鳥苷|環磷酸鳥苷]]，由此增加在性刺激時的陰莖血流量<ref name="molemech" />。這個作用機轉使得第五型磷酸二酯酶抑制劑在不受性刺激時不會發生作用。

==相關條目==
*{{tsl|en|Discovery and development of phosphodiesterase 5 inhibitors|第五型磷酸二酯酶抑制劑的發現與開發}}
==參考資料==
{{reflist|2}}
* {{cite journal |doi=10.1016/0005-2744(72)90060-5 |title=Separation of multiple molecular forms of cyclic adenosine-3′,5′-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis |year=1972 |last1=Uzunov |first1=Petko |last2=Weiss |first2=Benjamin |journal=Biochimica et Biophysica Acta |volume=284 |pages=220–6 |pmid=4342220 |issue=1}}
* {{Cite book |pmid=165666 |year=1975 |last1=Weiss |first1=Benjamin |title=Differential Activation and Inhibition of the Multiple Forms of Cyclic Nucleotide Phosphodiesterase |volume=5 |pages=195–211 |journal=Advances in Cyclic Nucleotide Research |isbn=978-0-89004-021-8}}
* {{cite journal |last1=Fertel |first1=Richard |last2=Weiss |first2=Benjamin |title=Properties and Drug Responsiveness of Cyclic Nucleotide Phosphodiesterases of Rat Lung |journal=Molecular Pharmacology |pmid=183099 |url=http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=183099 |year=1976 |volume=12 |issue=4 |pages=678–87}}
* {{cite journal |doi=10.1146/annurev.pa.17.040177.002301 |title=Selective Cyclic Nucleotide Phosphodiesterase Inhibitors as Potential Therapeutic Agents |year=1977 |last1=Weiss |first1=B |last2=Hait |first2=W N |journal=Annual Review of Pharmacology and Toxicology |volume=17 |pages=441–77 |pmid=17360}}
* {{cite journal |doi= 10.1002/14651858.CD003562.pub2|title=Sildenafil for pulmonary hypertension |journal=Cochrane Database of Systematic Reviews |year=2001 |last1=Kanthapillai |first1=Parthipan |last2=Lasserson |first2=Toby J |last3=Walters |first3=E. Haydn |pmid=15495058 |issue=4 |pages=CD003562}}

{{Phosphodiesterase inhibitors}}

[[分類:PDE5抑制剂|*]]
[[Category:性功能障碍药物|Category:性功能障碍药物]]
[[Category:肺循環疾病|Category:肺循環疾病]]
[[Category:男性生殖器官疾病|Category:男性生殖器官疾病]]